Zydus Lifesciences plans to acquire a majority stake in Ardelyx Inc. for $2.2-2.5 billion, funding the deal through a ₹5,000 crore equity raise. This acquisition aligns with Zydus’s strategy to expand into innovative medicines amid growing competition.
